Keana J F, Kher S M, Cai S X, Dinsmore C M, Glenn A G, Guastella J, Huang J C, Ilyin V, Lü Y, Mouser P L
Department of Chemistry, University of Oregon, Eugene 97403, USA.
J Med Chem. 1995 Oct 27;38(22):4367-79. doi: 10.1021/jm00022a003.
A series of mono-, di-, tri-, and tetrasubstituted 1,4-dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (Kb approximately 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (Kb = 0.9-1.5 microM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a approximately 100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a approximately 3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non-NMDA receptors.
合成了一系列单取代、二取代、三取代和四取代的1,4 - 二氢喹喔啉 - 2,3 - 二酮(QXs),并评估其作为N - 甲基 - D - 天冬氨酸(NMDA)/甘氨酸位点和α - 氨基 - 3 - 羟基 - 5 - 甲基异恶唑 - 4 - 丙酸偏好的非NMDA受体拮抗剂的活性。通过电测定法在表达大鼠全脑聚腺苷酸(poly(A)+)RNA的非洲爪蟾卵母细胞中测量拮抗剂效价。在5位含有硝基且在6和7位含有卤素的三取代QXs 17a(ACEA 1021)、17b(ACEA 1031)、24a和27,在甘氨酸位点显示出高效价(Kb约为6 - 8 nM),在非NMDA受体处为中等效价(Kb = 0.9 - 1.5 μM),并且在甘氨酸位点拮抗作用相对于非NMDA受体具有最高(120 - 250倍)的选择性。四取代QXs 17d、e作为甘氨酸位点拮抗剂比相应的三取代QXs弱100倍以上,在8位F作为取代基比Cl耐受性更好。与三取代类似物相比,二取代和单取代QXs显示出逐渐减弱的拮抗作用。例如,去除17a的5 - 硝基导致效价降低约100倍(10a、b、z),而从17a去除两个卤素导致效价降低约3000倍(10v)。就稳态抑制而言,大多数QX取代模式有利于在NMDA/甘氨酸位点的拮抗作用而非非NMDA受体处的拮抗作用。在所测试的QXs中,只有17i对非NMDA受体有轻微选择性。